Inclusion Criteria:

        Must fall into one of the three categories defined as high risk of developing pancreatic
        cancer:

          -  High Risk Group 1 (familial pancreatic cancer relatives):

               -  older than 55 years old or 10 years younger than the age of youngest relative
                  with pancreatic cancer, and

               -  Have 2 or more family members with a history of pancreatic cancer, and

               -  Have a first-degree relationship with at least one of the relatives with
                  pancreatic cancer.

          -  High Risk Group 2 (Has gene mutation(s) with an associated with an estimated lifetime
             risk of pancreatic cancer of approximately 10% or higher):

               -  50 years old and has FAMMM (p16/CDKN2A) gene mutation.

               -  older than 50 years old or 10 years younger than the age of the youngest relative
                  with pancreatic cancer, and

               -  Has known BRCA2, Acute Transverse Myelopathy (ATM), partner and localizer of
                  BRCA2 (PALB2) gene mutation, and

               -  There is more than 1 pancreatic cancer in the family, one of whom is a first- or
                  second-degree relative of the subject to be screened.

          -  High Risk Group 3 (Has gene mutation(s) with an associated with an estimated lifetime
             risk of pancreatic cancer of approximately 5%):

               -  Older than 55 years old or 10 years younger than the age of the youngest relative
                  with pancreatic cancer, and

               -  Has known BRCA1, or HNPCC (hereditary non-polyposis colorectal cancer or Lynch
                  syndrome, hMLH1, hMSH2, postmeiotic segregation 1(PMS1), human MutS homolog 6
                  (hMSH6), EpCAM) gene mutations, and

               -  There is more than 1 pancreatic cancer in the family, one of whom is a first- or
                  second-degree relative of the subject to be screened.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Patients must have adequate organ and marrow function defined by study-specified
             laboratory tests prior to initial study drug.

          -  Ability to understand and willingness to sign a written informed consent document.

          -  Woman of childbearing potential must have a negative pregnancy test and follow
             contraceptive guidelines as defined per protocol.

          -  Men must use acceptable form of birth control while on study.

        Exclusion Criteria:

          -  If expected to require any other form of systemic or localized antineoplastic therapy
             while on study.

          -  Within 4 weeks prior to first dose of study drug.

             o Any systemic or topical corticosteroids at immunosuppressive agents.

          -  Within 4 weeks prior to first dose of study drug.

               -  Any investigational device.

               -  Has received a live vaccine.

               -  Received any allergen hyposensitization therapy.

               -  Any major surgery.

          -  Infection with HIV or hepatitis B or C.

          -  Uncontrolled intercurrent illness including, but not limited to, uncontrolled
             infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia,
             metastatic cancer, or psychiatric illness/social situations that would limit
             compliance with study requirements monoclonal antibody.

          -  Has a diagnosis of immunodeficiency.

          -  Any other sound medical, psychiatric, and/or social reason as determined by the
             Investigator.

          -  Unwilling or unable to follow the study schedule for any reason.

          -  Are pregnant or breastfeeding.